Literature DB >> 26121081

Brain Imaging and Blood Biomarker Abnormalities in Children With Autosomal Dominant Alzheimer Disease: A Cross-Sectional Study.

Yakeel T Quiroz1, Aaron P Schultz2, Kewei Chen3, Hillary D Protas4, Michael Brickhouse5, Adam S Fleisher6, Jessica B Langbaum4, Pradeep Thiyyagura4, Anne M Fagan7, Aarti R Shah7, Martha Muniz8, Joseph F Arboleda-Velasquez9, Claudia Munoz10, Gloria Garcia10, Natalia Acosta-Baena10, Margarita Giraldo10, Victoria Tirado10, Dora L Ramírez10, Pierre N Tariot11, Bradford C Dickerson5, Reisa A Sperling12, Francisco Lopera10, Eric M Reiman13.   

Abstract

IMPORTANCE: Brain imaging and fluid biomarkers are characterized in children at risk for autosomal dominant Alzheimer disease (ADAD).
OBJECTIVE: To characterize and compare structural magnetic resonance imaging (MRI), resting-state and task-dependent functional MRI, and plasma amyloid-β (Aβ) measurements in presenilin 1 (PSEN1) E280A mutation-carrying and noncarrying children with ADAD. DESIGN, SETTING, AND PARTICIPANTS: Cross-sectional measures of structural and functional MRI and plasma Aβ assays were assessed in 18 PSEN1 E280A carriers and 19 noncarriers aged 9 to 17 years from a Colombian kindred with ADAD. Recruitment and data collection for this study were conducted at the University of Antioquia and the Hospital Pablo Tobon Uribe in Medellín, Colombia, between August 2011 and June 2012. MAIN OUTCOMES AND MEASURES: All participants had blood sampling, structural MRI, and functional MRI during associative memory encoding and resting-state and cognitive assessments. Outcome measures included plasma Aβ1-42 concentrations and Aβ1-42:Aβ1-40 ratios, memory encoding-dependent activation changes, resting-state connectivity, and regional gray matter volumes. Structural and functional MRI data were compared using automated brain mapping algorithms and search regions related to AD.
RESULTS: Similar to findings in adult mutation carriers, in the later preclinical and clinical stages of ADAD, mutation-carrying children were distinguished from control individuals by significantly higher plasma Aβ1-42 levels (mean [SD]: carriers, 18.8 [5.1] pg/mL and noncarriers, 13.1 [3.2] pg/mL; P < .001) and Aβ1-42:Aβ1-40 ratios (mean [SD]: carriers, 0.32 [0.06] and noncarriers, 0.21 [0.03]; P < .001), as well as less memory encoding task-related deactivation in parietal regions (eg, mean [SD] parameter estimates for the right precuneus were -0.590 [0.50] for noncarriers and -0.087 [0.38] for carriers; P < .005 uncorrected). Unlike carriers in the later stages, mutation-carrying children demonstrated increased functional connectivity of the posterior cingulate cortex with medial temporal lobe regions (mean [SD] parameter estimates were 0.038 [0.070] for noncarriers and 0.190 [0.057] for carriers), as well as greater gray matter volumes in temporal regions (eg, left parahippocampus; P < . 049, corrected for multiple comparisons). CONCLUSIONS AND RELEVANCE: Children at genetic risk for ADAD have functional and structural brain changes and abnormal levels of plasma Aβ1-42. The extent to which the underlying brain changes are either neurodegenerative or developmental remains to be determined. This study provides additional information about the earliest known biomarker changes associated with ADAD.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26121081      PMCID: PMC4625544          DOI: 10.1001/jamaneurol.2015.1099

Source DB:  PubMed          Journal:  JAMA Neurol        ISSN: 2168-6149            Impact factor:   18.302


  29 in total

1.  What is the best similarity measure for motion correction in fMRI time series?

Authors:  L Freire; A Roche; J F Mangin
Journal:  IEEE Trans Med Imaging       Date:  2002-05       Impact factor: 10.048

2.  Increased cortical thickness and caudate volume precede atrophy in PSEN1 mutation carriers.

Authors:  Juan Fortea; Roser Sala-Llonch; David Bartrés-Faz; Beatriz Bosch; Albert Lladó; Nuria Bargalló; José Luis Molinuevo; Raquel Sánchez-Valle
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

3.  A fast diffeomorphic image registration algorithm.

Authors:  John Ashburner
Journal:  Neuroimage       Date:  2007-07-18       Impact factor: 6.556

4.  Decreased effective connectivity from cortices to the right parahippocampal gyrus in Alzheimer's disease subjects.

Authors:  Guangyu Chen; B Douglas Ward; Gang Chen; Shi-Jiang Li
Journal:  Brain Connect       Date:  2014-11

5.  Pre-dementia clinical stages in presenilin 1 E280A familial early-onset Alzheimer's disease: a retrospective cohort study.

Authors:  Natalia Acosta-Baena; Diego Sepulveda-Falla; Carlos Mario Lopera-Gómez; Mario César Jaramillo-Elorza; Sonia Moreno; Daniel Camilo Aguirre-Acevedo; Amanda Saldarriaga; Francisco Lopera
Journal:  Lancet Neurol       Date:  2011-02-04       Impact factor: 44.182

6.  Event-related potential markers of brain changes in preclinical familial Alzheimer disease.

Authors:  Y T Quiroz; B A Ally; K Celone; J McKeever; A L Ruiz-Rizzo; F Lopera; C E Stern; A E Budson
Journal:  Neurology       Date:  2011-07-20       Impact factor: 9.910

7.  Plasma amyloid-β and risk of Alzheimer's disease in the Framingham Heart Study.

Authors:  Vincent Chouraki; Alexa Beiser; Linda Younkin; Sarah Rosner Preis; Galit Weinstein; Oskar Hansson; Ingmar Skoog; Jean-Charles Lambert; Rhoda Au; Lenore Launer; Philip A Wolf; Steven Younkin; Sudha Seshadri
Journal:  Alzheimers Dement       Date:  2014-09-10       Impact factor: 21.566

8.  Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study.

Authors:  Eric M Reiman; Yakeel T Quiroz; Adam S Fleisher; Kewei Chen; Carlos Velez-Pardo; Marlene Jimenez-Del-Rio; Anne M Fagan; Aarti R Shah; Sergio Alvarez; Andrés Arbelaez; Margarita Giraldo; Natalia Acosta-Baena; Reisa A Sperling; Brad Dickerson; Chantal E Stern; Victoria Tirado; Claudia Munoz; Rebecca A Reiman; Matthew J Huentelman; Gene E Alexander; Jessica B S Langbaum; Kenneth S Kosik; Pierre N Tariot; Francisco Lopera
Journal:  Lancet Neurol       Date:  2012-11-06       Impact factor: 44.182

9.  Cortical atrophy in presymptomatic Alzheimer's disease presenilin 1 mutation carriers.

Authors:  Yakeel T Quiroz; Chantal E Stern; Eric M Reiman; Michael Brickhouse; Adriana Ruiz; Reisa A Sperling; Francisco Lopera; Bradford C Dickerson
Journal:  J Neurol Neurosurg Psychiatry       Date:  2012-11-07       Impact factor: 10.154

10.  Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease.

Authors:  Randall J Bateman; Paul S Aisen; Bart De Strooper; Nick C Fox; Cynthia A Lemere; John M Ringman; Stephen Salloway; Reisa A Sperling; Manfred Windisch; Chengjie Xiong
Journal:  Alzheimers Res Ther       Date:  2011-01-06       Impact factor: 6.982

View more
  46 in total

1.  The Value of Pre-Screening in the Alzheimer's Prevention Initiative (API) Autosomal Dominant Alzheimer's Disease Trial.

Authors:  S Rios-Romenets; M Giraldo-Chica; H López; F Piedrahita; C Ramos; N Acosta-Baena; C Muñoz; P Ospina; C Tobón; W Cho; M Ward; J B Langbaum; P N Tariot; E M Reiman; F Lopera
Journal:  J Prev Alzheimers Dis       Date:  2018

2.  Brain structural alterations are distributed following functional, anatomic and genetic connectivity.

Authors:  Franco Cauda; Andrea Nani; Jordi Manuello; Enrico Premi; Sara Palermo; Karina Tatu; Sergio Duca; Peter T Fox; Tommaso Costa
Journal:  Brain       Date:  2018-11-01       Impact factor: 13.501

3.  Association Between Amyloid and Tau Accumulation in Young Adults With Autosomal Dominant Alzheimer Disease.

Authors:  Yakeel T Quiroz; Reisa A Sperling; Daniel J Norton; Ana Baena; Joseph F Arboleda-Velasquez; Danielle Cosio; Aaron Schultz; Molly Lapoint; Edmarie Guzman-Velez; John B Miller; Leo A Kim; Kewei Chen; Pierre N Tariot; Francisco Lopera; Eric M Reiman; Keith A Johnson
Journal:  JAMA Neurol       Date:  2018-05-01       Impact factor: 18.302

4.  Biological and Cognitive Markers of Presenilin1 E280A Autosomal Dominant Alzheimer's Disease: A Comprehensive Review of the Colombian Kindred.

Authors:  J T Fuller; A Cronin-Golomb; J R Gatchel; D J Norton; E Guzmán-Vélez; H I L Jacobs; B Hanseeuw; E Pardilla-Delgado; A Artola; A Baena; Y Bocanegra; K S Kosik; K Chen; P N Tariot; K Johnson; R A Sperling; E M Reiman; F Lopera; Y T Quiroz
Journal:  J Prev Alzheimers Dis       Date:  2019

5.  Cholinergic-like neurons carrying PSEN1 E280A mutation from familial Alzheimer's disease reveal intraneuronal sAPPβ fragments accumulation, hyperphosphorylation of TAU, oxidative stress, apoptosis and Ca2+ dysregulation: Therapeutic implications.

Authors:  Viviana Soto-Mercado; Miguel Mendivil-Perez; Carlos Velez-Pardo; Francisco Lopera; Marlene Jimenez-Del-Rio
Journal:  PLoS One       Date:  2020-05-21       Impact factor: 3.240

Review 6.  Revolution of Resting-State Functional Neuroimaging Genetics in Alzheimer's Disease.

Authors:  Patrizia A Chiesa; Enrica Cavedo; Simone Lista; Paul M Thompson; Harald Hampel
Journal:  Trends Neurosci       Date:  2017-07-03       Impact factor: 13.837

7.  Autosomal Dominantly Inherited Alzheimer Disease: Analysis of genetic subgroups by Machine Learning.

Authors:  Diego Castillo-Barnes; Li Su; Javier Ramírez; Diego Salas-Gonzalez; Francisco J Martinez-Murcia; Ignacio A Illan; Fermin Segovia; Andres Ortiz; Carlos Cruchaga; Martin R Farlow; Chengjie Xiong; Neil R Graff-Radford; Peter R Schofield; Colin L Masters; Stephen Salloway; Mathias Jucker; Hiroshi Mori; Johannes Levin; Juan M Gorriz
Journal:  Inf Fusion       Date:  2020-01-07       Impact factor: 12.975

8.  Tau Accumulation in Clinically Normal Older Adults Is Associated with Hippocampal Hyperactivity.

Authors:  Willem Huijbers; Aaron P Schultz; Kathryn V Papp; Molly R LaPoint; Bernard Hanseeuw; Jasmeer P Chhatwal; Trey Hedden; Keith A Johnson; Reisa A Sperling
Journal:  J Neurosci       Date:  2018-11-27       Impact factor: 6.167

Review 9.  Alzheimer's Disease Genetic Risk Factor APOE-ε4 Also Affects Normal Brain Function.

Authors:  Amanda M Di Battista; Nicolette M Heinsinger; G William Rebeck
Journal:  Curr Alzheimer Res       Date:  2016       Impact factor: 3.498

10.  Increases of Plasma Levels of Glial Fibrillary Acidic Protein, Tau, and Amyloid β up to 90 Days after Traumatic Brain Injury.

Authors:  Tanya Bogoslovsky; David Wilson; Yao Chen; David Hanlon; Jessica Gill; Andreas Jeromin; Linan Song; Carol Moore; Yunhua Gong; Kimbra Kenney; Ramon Diaz-Arrastia
Journal:  J Neurotrauma       Date:  2016-07-08       Impact factor: 5.269

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.